These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35354411)

  • 21. Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial.
    Lickliter J; Kanceva R; Vincent E; Schueler A; Harrison-Moench E; Yue CS; Stahl M; Ullmann M; Ghori V; Griffin P
    Clin Ther; 2020 Aug; 42(8):1508-1518.e1. PubMed ID: 32660769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing the pharmacokinetics, safety, and immunogenicity of HLX02 to US- and EU-approved trastuzumab in healthy Chinese male subjects: A Phase I, randomized, double-blind, parallel-group study.
    Zhou W; Wang M; Yu Y; Wang J; Wu Y; Yang G; Yu H; Li J; Zhou L; Zhang Q
    Expert Opin Biol Ther; 2023; 23(8):717-725. PubMed ID: 36843059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults.
    Wynne C; Hamilton P; McLendon K; Stroissnig H; Smith M; Duijzings P; Ruffieux R; Otto H; Sattar A; Haliduola HN; Leutz S; Berti F
    Expert Opin Investig Drugs; 2023 May; 32(5):417-427. PubMed ID: 37212315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males.
    Kim A; Hong JH; Shin W; Yoo H; Jung JG; Reginster JY; Kim S; Bae Y; Suh J; Kim S; Lee E; Silverman S
    Expert Opin Biol Ther; 2024 Jul; 24(7):655-663. PubMed ID: 38349618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects.
    Lee HA; Kim S; Seo H; Kim S
    Expert Opin Investig Drugs; 2023; 32(10):959-966. PubMed ID: 37870163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab.
    Hummel M; Bosje T; Shaw A; Liu MS; Barve A; Kothekar M; Socinski MA; Waller CF
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):487-496. PubMed ID: 33866430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin
    Lickliter JD; Dadhania RN; Trivedi RK; Naveen Kumar SR; Reddy PK
    Indian J Med Res; 2021 Mar; 154(3):509-519. PubMed ID: 35142643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
    Park W; Božić-Majstorović L; Milakovic D; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Molina FFC; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Garmish O; Linde T; Rekalov D; Hrycaj P; Krause A; Fomina N; Piura O; Abello-Banfi M; Suh CH; Shim SC; Lee SJ; Lee SY; Kim SH; Yoo DH
    MAbs; 2018; 10(6):934-943. PubMed ID: 30010481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin
    Wynne C; Schwabe C; Batra SS; Lopez-Lazaro L; Kankanwadi S
    Br J Clin Pharmacol; 2018 Oct; 84(10):2352-2364. PubMed ID: 29943831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects.
    Wynne C; Altendorfer M; Sonderegger I; Gheyle L; Ellis-Pegler R; Buschke S; Lang B; Assudani D; Athalye S; Czeloth N
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1361-1370. PubMed ID: 27813422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin
    Li H; Zhao X; Xie J; Zhu X; Su Y; He C; Ding J; Zhu M; Xu Y; Wang Y; Shan R; Liu B; Ding Y; Liu Y; Zhou H; Xie Y
    BMC Pharmacol Toxicol; 2023 May; 24(1):36. PubMed ID: 37245022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial.
    Guo Y; Guo T; Di Y; Xu W; Hu Z; Xiao Y; Yu H; Hou J
    Expert Opin Biol Ther; 2023; 23(8):705-715. PubMed ID: 36892190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST).
    Wynne C; Schwabe C; Lemech C; Stroissnig H; Dias R; Sobierska J; Guenzi E; Otto H; Sattar A; Kay R; Haliduola HN; Berti F
    Expert Opin Investig Drugs; 2022 Sep; 31(9):965-976. PubMed ID: 35107050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods.
    von Richter O; Lemke L; Haliduola H; Fuhr R; Koernicke T; Schuck E; Velinova M; Skerjanec A; Poetzl J; Jauch-Lembach J
    Expert Opin Biol Ther; 2019 Oct; 19(10):1075-1083. PubMed ID: 30698045
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT-P47 and Reference Tocilizumab: A Randomized, Double-Blind, Phase 1 Study.
    Haranaka M; Eto T; Tanaka T; Yazawa R; Burmester G; Keystone E; Kim S; Bae Y; Suh J; Yang G; Kim Y; Lee J; Smolen JS
    J Clin Pharmacol; 2024 Oct; ():. PubMed ID: 39415551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.
    Hyland E; Mant T; Vlachos P; Attkins N; Ullmann M; Roy S; Wagner V
    Br J Clin Pharmacol; 2016 Oct; 82(4):983-93. PubMed ID: 27285856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TROIKA-1: A double-blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU-Herceptin
    Demarchi M; Coliat P; Mclendon K; Chung Shii Hii J; Feyaerts P; Ang F; Jaison L; Deforce F; Derde MP; Kim MJ; Park LS; Detappe A; Pivot X
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00839. PubMed ID: 34309241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
    Hillson J; Mant T; Rosano M; Huntenburg C; Alai-Safar M; Darne S; Palmer D; Pavlova BG; Doralt J; Reeve R; Goel N; Weilert D; Rhyne PW; Chance K; Caminis J; Roach J; Ganguly T
    Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study.
    Andersen G; Singh G; Murugesan SMN; Gogineni R; Sharma N; Panda J; Marwah A; Loganathan S; Athalye SN
    Diabetes Obes Metab; 2023 Jun; 25(6):1485-1494. PubMed ID: 36708333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra
    Zhang H; Li X; Liu J; Li C; Wu M; Zhu X; Sun J; Fang M; Ding Y
    Ann Med; 2021 Dec; 53(1):375-383. PubMed ID: 33629921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.